Patients are overconfident in their ability to operate drug delivery medical devices and may not realize that they are using them incorrectly, a comprehensive survey by the U.K.'s Team Consulting shows.
Cynapsus reported that 14 of the 16 Parkinson's disease patients responded positively in the Phase II trial of its reformulated thin-film strip version of the drug apomorphine, dubbed APL-130277, for the treatment of "off" episodes.
Delivery giant Catalent bought out Micron Technologies, a company that specializes in particle size engineering. The acquisition gives Catalent a leg up in early-stage drug development, according to a release, adding to its slate of oral and inhaled technologies.
Cynapsus Therapeutics touted the results of its Phase 2 clinical trial of its sublingual thin-film-strip formulation of apomorphine for the management of OFF motor symptoms of Parkinson's disease.
Researchers at the University of California in San Diego have developed a way to disguise the genetic material itself so that it can enter cells and shut down genetic diseases at the core.
Flowonix, maker of the implantable Prometra infusion pump for chronic pain patients, announced that it has raised $40 million in debt and equity financing led by private equity fund Élevage Capital Management.
Medical marijuana company CannScience Innovations entered into a nonbinding agreement to license Generex Biotechnology's RapidMist device for the buccal delivery of its developmental stage medical marijuana products.
The National Science Foundation this week awarded a second research grant to the maker of the only FDA-cleared catheter for rectal delivery of medication and liquids to expand the device's use beyond the hospice.
Eye care company Ocular Therapeutix today announced the results of its Phase II trial of its Sustained Release Dexamethasone aimed at treating allergic conjunctivitis. The 42-day randomized, double-blind study of 68 patients showed that patients on the candidate had lower ocular itching and conjunctival redness scores than those on the placebo, the company said.
HIV/AIDS prevention can be difficult in countries with limited resources, especially when it comes to the millions of affected children who are less likely to tolerate antiretroviral drugs. In an effort to overcome this challenge, researchers at Penn State University have developed a delivery system for the antiretroviral Ritonavir that uses a protein in cow's milk for oral administration of the drug.
Alnylam today announced the addition of RNA interference therapies for the hepatitis delta virus and chronic liver infections to its clinical pipeline at the American Association for the Study of Liver Diseases in Boston. The company also said it remains on track to select a candidate for its hepatitis B program by the end of the year and hopes to file an investigational new drug application with the FDA in late 2015.
RNA interference specialist Arrowhead presented new data from an ongoing Phase IIa study of its hepatitis B treatment ARC-520, demonstrating a reduction of the disease's surface antigens in what the company says is a first for RNAi.
Exton, PA's West Pharmaceutical Services just announced that the FDA has given it 510(k) clearance for the NovaGuard Staked-needle Automatic safety system, as the push to avoid needlestick injuries gathers momentum.
Scientists from Nevada's Roseman University of Health Sciences presented their work on a nasal spray formulation of the antipsychotic prochlorperazine for the treatment of migraines at the American Association of Pharmaceutical Scientists annual meeting in San Diego.
The FDA has accepted OptiNose's new drug application for the drug/device combination product candidate AVP-825 for the treatment of headaches.
Researchers at Imperial College London have created an artificial cell with separate compartments that can communicate with one another via chemical reactions, much the way, for instance, the nucleus would communicate with other parts of the cell.
The FDA recently gave 510(k) clearance to a two-balloon catheter for the targeted delivery of diagnostic and therapeutic agents to the visceral vascular system. This subset of the peripheral vasculature consists of the arteries that supply blood to the intestines, spleen and liver.
The University of Manchester's North West Centre for Advanced Drug Delivery will study drug delivery topics in cancer and other diseases of interest to the AstraZeneca, in the latest example of the growing research collaboration between Big Pharma and academia.
With small but prestigious contributions from the scientific community, SQZ Biotech is looking to launch its CellSqueeze platform to be used in commercial applications.
In addition to being blockbuster drugs, Nexium, the Advair Diskus and Rituxan all have a half-life of less than 6 hours and target circadian genes, meaning that their efficacy could be influenced by the timing of their administration due to the so-called biological/molecular clock, according to University of Pennsylvania researchers.